Automation-enabled assay development for high throughput screening

Respective assays range from simple binding analysis to complex phenotypic assays with multiple read-out parameters. In order to understand the molecular mode of action (mMoA) of compounds as early as possible in the drug identification process, Merck also implement mMoA assays, such as competition assays or jump dilution assays into the HTS campaigns.
In this webinar, Dr. Nina Grossmann and Adrian Schoen of Discovery Pharmacology at Merck, Darmstadt, will explore how they use the dragonfly discovery to quickly set up robust high-throughput assays.